Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2011


Here are the related meetings in 2018:
Phosphoinositide Biology: New Therapeutic Targets Beyond Class I PI3K (B5)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Inositide Signaling in Pharmacology and Disease (X1)


Organizer(s) Marco Falasca, Nullin Divecha, John D. York and Pietro V. De Camilli
February 13—18, 2011
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 14, 2010
Late Abstract Deadline: Nov 18, 2010
Scholarship Deadline: Oct 14, 2010
Early Registration Deadline: Dec 14, 2010

Sponsored by sanofi-aventis


Summary of Meeting:
Phosphoinositide and inositol phosphates interact with and modulate the recruitment and activation of key regulatory proteins and in doing so control diverse functions including cell growth and proliferation, apoptosis, cytoskeletal dynamics, insulin action, vesicle trafficking and nuclear function. Initially, inositide signaling was limited to the PLC pathway; however, it is now clear that all the seven phosphoinositides and more than 30 different inositol phosphates likely have specific signaling functions. Moreover there is a growing list of proteins that are regulated by inositol signaling. This has raised the question as to how inositol signaling can control diverse processes and yet maintain signaling specificity. Controlling the levels of inositol signaling molecules and their subcellular compartmentalisation is likely to be critical. This meeting will bring together scientists from different backgrounds to discuss how understanding inositol signaling may be used to target complex human diseases that manifest themselves when inositol signaling is deregulated.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, FEBRUARY 13

15:00—19:30
Registration

Longs Peak Foyer
18:15—19:15
Refreshments

Longs Peak Foyer
19:15—19:30
Welcome Address (Joint, on behalf of both meetings)

Longs/Grays Peak
* Sabina C. Cosulich, AstraZeneca, UK

19:30—21:30
Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Robin F. Irvine, University of Cambridge, UK

Robert H. Michell, University of Birmingham, UK
Inositol Phospholipids: Origins and Evolution of Functions

Lewis C. Cantley, Weill Cornell Medicine, USA
The Role of Phosphoinositides in Human Disease


MONDAY, FEBRUARY 14

07:00—08:00
Breakfast

Quandary Peak
08:00—11:15
Phosphoinositide 3-Kinase Signaling in Disease: Class 1 PI3Ks (Joint)
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Marco Falasca, Barts & The London School of Medicine & Dentistry, UK

* David A. Fruman, University of California, Irvine, USA

Bart Vanhaesebroeck, University College London, Cancer Institute, UK
Direct and Indirect Actions of PI3K in Cancer

Roger L. Williams, Medical Research Council, UK
Structural Insights into PI3K Isoform-Specific Signaling

Len R. Stephens, Babraham Institute, UK
Mass Spectrometry based Measurement of PtdIns(3,4,5)P3 Molecular Species

Ana Clara Carrera, Centro Nacional Biotechnologia/CSIC, Spain
PI3K Isoforms Function in Inflammation and Cancer

Katarina Ejeskär, Probion Innovation Sweden, Sweden
Short Talk: p37delta, a New Isoform of PI3K p110delta, Increases Cell Proliferation in vitro and in vivo

Deborah H. Anderson, Saskatchewan Cancer Agency, Canada
Short Talk: Regulation of PTEN by the p85 Subunit of Phosphatidylinositol 3-Kinase (PI3K)

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Quandary Peak
13:00—22:00
Poster Viewing

Quandary Peak
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Other Phosphoinositide Kinases
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Pietro V. De Camilli, Yale University School of Medicine, USA

Nullin Divecha, University of Southampton, UK
PIP2 Synthesis

Robin F. Irvine, University of Cambridge, UK
Inositide Kinases and their Products - A Matter of Location

Scott D. Emr, Cornell University, USA
Phosphoinositide Signaling and Membrane Traffic: Regulation of PIP Phosphatases

Assia Shisheva, Wayne State University School of Medicine, USA
Short Talk: PIKfyve-ArPIKfyve-Sac3 Protein Machinery to Orchestrate Coordinated Regulation of PI(3,5)P2 Synthesis and Turnover in Mammalian Cells


Following Session is for PI 3-Kinase Signaling Pathways (X2)

17:00—19:00
PI 3-Kinase and Signaling: Non-Class I PI3Ks
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Bart Vanhaesebroeck, University College London, Cancer Institute, UK

Takehiko Sasaki, Akita University School of Medicine, Japan
Role for 3-Phosphoinositide Metabolism in vivo

Jonathan M. Backer, Albert Einstein College of Medicine, USA
Regulation of Class I and Class III PI 3-Kinases

David Harris, Lexicon Pharmaceuticals, Inc., USA
Short Talk: Requirement for the Class II Phosphoinositide 3-Kinase C2alpha in Maintenance of Glomerular Structure and Function

Tania Maffucci, Queen Mary University of London, UK
Short Talk: Role of Class II Phosphoinositide 3-Kinase alpha in Diabetes

Frederic A. Meunier, Queensland Brain Institute, Australia
Short Talk: Fine-Tuning of Neuroexocytosis by Two Members of the PI3-Kinase Family: Type I PI3Kdelta and Type II PI3K-C2alpha

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
19:30—22:00
Poster Session 1

Quandary Peak

TUESDAY, FEBRUARY 15

07:00—08:00
Breakfast

Quandary Peak
08:00—11:15
Phosphoinositides in Signaling and Disease
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Scott D. Emr, Cornell University, USA

Vojo Deretic, University of New Mexico Health Sciences Center, USA
Autophagy: Good or Bad in Cancer

Bernard Payrastre, INSERM, France
Phosphoinositide Signaling and Diseases: A Role for PtdIns5P

Peter J. Cullen, University of Bristol, UK
Phosphoinositides and the Regulation of the Endo-Lysosomal Network

Tamas Balla, NICHD, National Institutes of Health, USA
Detection and Rapid Manipulation of Phosphoinositides in Living Cells

Amy Kiger, University of California, San Diego, USA
Short Talk: Coordinated PI3KC2/Mtm Phosphoinositide Regulation and Rab activity in Membrane Trafficking and Disease

Xinjiang Cai, Skirball Institute of Biomolecular Medicine, NYU Medical Center, USA
Short Talk: Negative Regulation of CD4 T Cell Activation by Tripartite Motif Containing Protein 27 via the Ubiquitination and Inhibition of the Class II Phosphatidylinositol 3 Kinase C2-beta


Following Session is for PI 3-Kinase Signaling Pathways (X2)

08:00—11:15
Downstream of PI 3-Kinase: Akt, mTOR and Metabolism
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA

Alex Toker, Beth Israel Deaconess Medical Center, USA
Akt Isoform Specificity in Breast Cancer Cell Signaling

Brendan D. Manning, Harvard School of Public Health, USA
mTOR Controls Cellular Metabolism Downstream of PI3K

Joan S. Brugge, Harvard Medical School, USA
PI3K Pathway in Tumor Cell Metabolism and Matrix Control

Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Activation of the PI3K Pathway is Essential for Cell Autonomous Nutrient Uptake

James Brugarolas, UT Southwestern Medical Center, USA
Short Talk: Regulation of V-ATPases and Endocytosis by mTORC1

David A. Fruman, University of California, Irvine, USA
Short Talk: TOR Inhibitors Promote Activity of FOXO Transcription Factors in Lymphocytes

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Quandary Peak
13:00—22:00
Poster Viewing

Quandary Peak
11:15
On Own for Lunch and Recreation

14:30—16:30
Workshop: Novel Experimental Approaches to Investigate Phosphoinositide Signalling

Grays Peak
* Tamas Balla, NICHD, National Institutes of Health, USA

Thomas Masters, Mechanobiology Institute, Singapore
Evidence for a Fence that Impedes the Diffusion of Phosphatidylinositol 4,5-Bisphosphate (PIP2) Out of the Forming Phagosomes of Macrophages

Dominik Oliver, University of Marburg, Germany
Voltage Sensitive Phosphatases as Tools for Characterizing Phosphoinositide Sensors and Effectors

Qisheng Zhang, University of North Carolina at Chapel Hill, USA
Small Molecule Reporters and Modulators for Mammalian Phospholipase C Isozymes

Wonhwa Cho, University of Illinois at Chicago, USA
In Situ Quantitative Imaging of Phosphoinositides

Gerry Hammond, University of Cambridge, UK
Dissecting the Roles of Plasma Membrane PtdIns4P and PtdIns(4,5)P2

Lucia E. Rameh, Boston Biomedical Research Institute, USA
A New Mechanism for Regulating the PI-5-P Pathway for PI-4,5-P2 Synthesis in Response to Changes in the Extracellular Environment

Jeffrey R. Peterson, Fox Chase Cancer Center, USA
Phosphoinositides are Essential Co-Activators for p21-Activated Kinase 1 (Pak1)

Michael J. Schell, Uniformed Services University, USA
F-Actin Binding by Inositol Trisphosphate 3-Kinase: A Recent Evolutionary Elaboration for Localized IP3 Control and Structural Plasticity in Dendritic Spines

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Phosphoinositide Metabolism
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Nullin Divecha, University of Southampton, UK

Pietro V. De Camilli, Yale University School of Medicine, USA
Phosphoinositide Metabolism in Endocytic Membrane Traffic

Shamshad Cockcroft, University College London, UK
Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer or Binding the Key to Function Phosphatidylinositol Transfer Proteins: Is Phosphatidylinositol Transfer Activity Required for Function?

Lois S. Weisman, University of Michigan, USA
Roles of Phosphatidylinositol 3,5 bis Phosphate, a Lipid with Unexpected Links to Neurodegenerative Disease

Dave Bridges, University of Michigan, USA
Short Talk: Endolysosomal Phosphatidylinositides and the Regulation of TORC1 Localization and Function


Following Session is for PI 3-Kinase Signaling Pathways (X2)

17:00—19:00
Therapeutic Strategies in the PI 3-Kinase Pathway
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Sabina C. Cosulich, AstraZeneca, UK

Christian Rommel, F. Hoffmann-La Roche Ltd, Switzerland
Targeting PI3Kalpha and TORC1/2 Alone or in Combination for the Treatment of Solid Tumor

Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
PI3K Pathways in Cancer, Mechanistic Insights

Jeffrey A. Engelman, Novartis Institutes of BioMedical Research, USA
Optimizing PI3K Targeting in Cancer, Mechanistic Insights

Kyle A. Edgar, Genentech, Inc., USA
Short Talk: PI3K Pathway Signaling Promotes an Invasive Phenotype that is Independent of Akt

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
19:30—22:00
Poster Session 2

Quandary Peak

WEDNESDAY, FEBRUARY 16

07:00—08:00
Breakfast

Quandary Peak
08:00—11:15
Phosphoinositide Phosphatases (Joint)
Meeting has ended...abstracts no longer viewable online.

Longs/Grays Peak
* Lewis C. Cantley, Weill Cornell Medicine, USA

* Bernard Payrastre, INSERM, France

Ramon Parsons, Icahn School of Medicine at Mount Sinai, USA
The Role of PTEN Signaling Perturbations in Cancer and in Targeted Therapy

Jocelyn Laporte, Institute of Genetics and Molecular and Cellular Biology, France
Myotubularins and Associated Neuromuscular Diseases

Stéphane Schurmans, Universite de Liège, Belgium
Functional Characterization of PI 5-Phosphatases and IP 3-Kinases in Mice

Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
The Unanticipated Role of an Extended miRNA Proto-Oncogenic Network in the Modulation of PTEN-PI3K Signalling Output

Christina Anne Mitchell, Monash University, Australia
Short Talk: INPP4B – a Putative Tumour Suppressor in Human Breast Cancer

Wayne Bowden, Florida International University College of Medicine, USA
Short Talk: Inositol Polyphosphate 4-Phosphatase Type II, INPP4B, is an Androgen Induced Tumor Suppressor in Prostate Cancer

09:20—09:40
Coffee Break

Longs Peak Foyer
11:15—13:00
Poster Setup

Quandary Peak
13:00—22:00
Poster Viewing

Quandary Peak
11:15
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Inositol Phosphates Signaling
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* John D. York, Vanderbilt University, USA

Lucio Cocco, University of Bologna, Italy
Nuclear Inositide Signaling (PI-PLCbeta1: from Bench to Clinics)

Marco Falasca, Barts & The London School of Medicine & Dentistry, UK
Role of Phospholipase C in Cell Metastasis

John Condeelis, Albert Einstein College of Medicine, USA
Phosphoinositol Regulation of Breast Tumor Cell Chemotaxis and Metastasis

Chris Noakes, University of Manchester, UK
Short Talk: The PH Domain Proteins IPIP27A and B (Ses1/2) Link OCRL1 to Receptor Recycling in the Endocytic Pathway


Following Session is for PI 3-Kinase Signaling Pathways (X2)

17:00—19:00
Mouse Models of Class I PI3K in Disease
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Len R. Stephens, Babraham Institute, UK

Klaus Okkenhaug, Babraham Institute, UK
PI3K p110delta in T Cell Immunity and Inflammation

Emilio Hirsch, Fondazione per la Ricerca Biomedica – ONLUS, Italy
p110gamma in Immunity, Inflammation and Cardiac Context

Jean J. Zhao, Dana-Farber Cancer Institute, USA
Targeting PI3K in Cancer, Mechanistic Insights from Genetic Mouse Models

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
19:30—22:00
Poster Session 3

Quandary Peak

THURSDAY, FEBRUARY 17

07:00—08:00
Breakfast

Quandary Peak
08:00—11:00
Inositides and Ion Channels
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Shamshad Cockcroft, University College London, UK

Bertil Hille, University of Washington, USA
PIP2 is a Necessary Cofactor for Ion Channel Function: Biophysical Studies of Phosphoinositides in Living Cells

Victoria M. Bolotina, Boston Medical Center, USA
Store-Operated Channels: What Makes Them Tick?

James W. Putney, Jr., NIEHS, National Institutes of Health, USA
Regulation and Physiological Function of Store-Operated Calcium Entry

Ivan F. Gonzalez, University of Washington, USA
Short Talk: Phosphoinositide Regulation of TRPV1 Sensitization during Inflammatory Hyperalgesia

Yuxin Mao, Cornell University, USA
Short Talk: Crystal Structure of the Yeast Sac1: Implications for Its Phosphoinositide Phosphatase Function

Peter Mayinger, Oregon Health and Science University, USA
Short Talk: Metabolic Control of Phosphoinositide Phosphatase Sac1 via the HOG MAP Kinase Pathway and Calcineurin


Following Session is for PI 3-Kinase Signaling Pathways (X2)

08:00—11:00
PI 3-Kinase Pathway Inhibitors – Preclinical and Clinical Studies I
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Christian Rommel, F. Hoffmann-La Roche Ltd, Switzerland

Kevan M. Shokat, University of California, San Francisco, USA
Chemical Genetic Investigations of Protein and Lipid Kinase Signaling

Neill A. Giese, , USA
Targeting PI3K Delta: A New Paradigm for the Treatment of B Cell Malignancies that Involves the Tumor Cell and it’s Microenvironment

David Finlay, School of Life Sciences, University of Dundee, Scotland
Akt is dispensable for a T Cell Nutrient Uptake and Metabolism

Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
A Systems Biology Approach to Monitor the PI3K Pathway

Jordi Rodon, Vall d'hebron University Hospital, Spain
Short Talk: Strategies for Selecting Patients with Tumors Harboring Alterations in the pI3K Pathway in Early Development of PI3K/akt/mTOR Inhibitors

Augustin Amour, GlaxoSmithKline, UK
Short Talk: PI3Kdelta Inhibition: A Future Paradigm for the Inhaled Therapy of Asthma?

09:20—09:40
Coffee Break

Longs Peak Foyer
11:00
On Own for Lunch and Recreation


Following Session is for PI 3-Kinase Signaling Pathways (X2)

14:30—16:30
Workshop: Experience with PI 3-Kinase Inhibitors in the Clinic
Details to be Announced

Longs Peak
* José Baselga, Memorial Sloan-Kettering Cancer Center, USA

16:30—17:00
Coffee Available

Longs Peak Foyer
17:00—19:00
Inositol Polyphosphates Signaling
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Lucio Cocco, University of Bologna, Italy

Adolfo Saiardi, University College London, UK
Are Inositol Pyrophosphates Signaling Molecules?

John D. York, Vanderbilt University, USA
Inositol Polyphosphates Kinases

Susan R. Wente, Vanderbilt University Medical Center, USA
Little Things that do a lot: Inositol Polyphosphates in DNA Repair

Les A. Hanakahi, University of Illinois at Chicago, Rockford Campus, USA
Short Talk: Inositol Polyphosphates: Effect on PI3K-Related Protein Kinase Substrate Selection


Following Session is for PI 3-Kinase Signaling Pathways (X2)

17:00—19:00
PI 3-Kinase Pathway Inhibitors – Clinical Studies II
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Lori Friedman, Genentech, Inc., USA

Langdon Miller, Calistoga Pharmaceuticals Inc, USA
CAL-101 Inhibition of PI3K-delta Demonstrates Clinical and Pharmacodynamic Activity as a New Therapeutic Approach to Lymphoid Malignancies

José Baselga, Memorial Sloan-Kettering Cancer Center, USA
Ongoing Clinical Studies with PI3K Inhibitors in Cancer Patients

Mika Derynck, Genentech, Inc., USA
Clinical Development Strategies of PI3K/mTOR Inhibitors

Jeffrey J. Wallin, Genentech, Inc., USA
Short Talk: Mutant PIK3CA Increases Microtubule Levels and Promotes Resistance to Anti-Mitotic Chemotherapy Drugs


Following Session is for PI 3-Kinase Signaling Pathways (X2)

19:00—19:15
Concluding Remarks
Meeting has ended...abstracts no longer viewable online.

Longs Peak
* Ramon Parsons, Icahn School of Medicine at Mount Sinai, USA

19:00—20:00
Social Hour with Lite Bites

Quandary Peak
20:00—23:00
Entertainment

Quandary Peak

FRIDAY, FEBRUARY 18

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13NS073206-01




National Institutes of Health

Grant No. 5R13DK084688-02




We gratefully acknowledge additional support for this conference from:

Avanti Polar Lipids, Inc. Sanofi US

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676